Home2026February

Monthly Archives: February, 2026

Amgen advances toward lupus redemption while gastric cancer candidate struggles

Julian English -
Amgen’s lupus efforts may be about to succeed. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2...

Phase 3 antifungal trial cancelled over low response, higher mortality rate

Julian English -
Pulmocide’s phase 3 trial has been cancelled after patients who received its investigational inhaled antifungal had lower response rates and a higher number of...

Hutchmed to file for approval of sovleplenib in China in the first half of 2026

Julian English -
A phase 3 trial of Hutchmed’s autoimmune disease candidate sovleplenib has hit ts primary endpoint, delivering a boost to an asset that was held...

Basilea to collaborate with US biotech to develop new antifungal drug

Julian English -
Basilea Pharmaceutica is continuing its quest to develop much-needed new antifungal drugs by penning a deal with Prokaryotics.  The collaboration will see Switzerland-based Basilea and...

Nanoform outlicenses Nanoencorafenib and signs development and commercialisation agreement with A.forall and IMGA

Julian English -
Nanoform has announced that it has established, in collaboration with A.forall Development NV, a wholly owned subsidiary of Boston-based private equity company The Riverside...

Most Read